Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation
Nurix anticipates nominating a clinical candidate within the first year of the extension
“STAT6 is a key transcription factor within the IL-4/IL-13 signaling pathways which act as drivers of inflammation in allergic conditions. These conditions are currently treated with injectable monoclonal antibody therapies, which are designed to impede IL-4/IL-13 signaling,” said
“The extension of the STAT6 research program with Sanofi speaks to the success of our current collaboration which combines Nurix’s leadership in the design and development of targeted protein degraders with Sanofi’s industry-leading expertise and capabilities in inflammation and immunology,” said
Under the collaboration agreement, Nurix is deploying its proprietary drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets. Sanofi has an option to license drug candidates resulting from the work, and Nurix retains its option to co-develop and co-promote future products in
About STAT6
Targeting the STAT6 pathway is supported by both insight from human genetic studies and clinical validation with either biologics targeting IL4/13 or small molecule inhibitors targeting the Janus Kinase (JAK) family. JAK proteins, which are upstream of STAT6, mediate the signaling of multiple cytokines, and as a result, JAK inhibition leads to safety concerns. A selective potent STAT6 degrader offers potential of antibody like efficacy with a better pathway specific profile compared to JAK inhibitors.
About
Forward-Looking Statements
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: Nurix’s future financial or business performance; Nurix’s plans with respect to its collaboration with Sanofi; Nurix’s expectations with respect to nominating a clinical candidate from the STAT6 program; the potential benefits of and Nurix’s expectations with respect to the extension of the research period under Nurix’s collaboration with Sanofi, including the potential achievement of milestone and license payments; the extent to which future development candidates, including targeted protein degraders of STAT6, may address a range of diseases; and the potential advantages of Nurix’s scientific approach and DELigase™ platform. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions regarding the future. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) the ability of each party to perform its obligations under the Nurix-Sanofi collaboration; (ii) whether the parties will be able to successfully conduct and complete preclinical development, clinical development and commercialization of any drug candidates under the Nurix-Sanofi collaboration; (iii) the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development; (iv) whether Nurix will be able to fund development activities and achieve development goals, including those under the Nurix-Sanofi collaboration; (v) risks and uncertainties relating to the timing and receipt of payments from Nurix’s collaboration partners, including milestone payments and royalties on future potential product sales; and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Annual Report on Form 10-K for the fiscal year ended
Contacts:
Investors
ir@nurixtx.com
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
areynolds@wheelhouselsa.com
Source:
2024 GlobeNewswire, Inc., source